Dibenzo[a,l]pyrene (DBP) is one of the most potent bacterial mutagen and mammary carcinogens. When DBP (50 µM) was incubated with calf thymus DNA (300 µg/ml) in the presence of liver microsomes from β-naphthoflavone (β-NF)-or Aroclor 1254-treated rats, at least eight adduct spots were detected as analyzed by nuclease P1-enhanced 32 P-postlabeling assay. DNA adduction was enhanced by nearly 20-and 60-fold with β-NF-and Aroclor 1254-induced microsomes, respectively, as compared with uninduced microsomes, suggesting a possible involvement of CYP1A family in DBP activation. Inclusion of the selective P4501A1 inhibitor, α-naphthoflavone (50 µM) in the activation reaction almost completely (>98%) abolished adduct formation further supporting involvement of P4501A in DBP activation. Analysis of DNA and 2Ј-deoxynucleosides 3Ј-mononucleotide reacted with anti-and syn-DBP-11,12-diol-13,14-epoxides (DBPDEs) and co-chromatography analyses in multiple solvents showed that the microsomal DBPϪDNA adducts were derived by interaction of both anti-and synDBPDEs with adenine and guanine in DNA in the following order: anti-DBPDE-dA~syn-DBPDE-dG >> anti-DBPDEdG~syn-DBPDE-dA. It is concluded that (i) most or all DBP adducts were P4501A-mediated; (ii) both the antiand syn-stereoisomers were involved in the DNA adduct formation; and (iii) both adenine and guanine in the DNA contributed equally to the formation of the major and minor adducts.
Introduction
Polycyclic aromatic hydrocarbons (PAHs*) are ubiquitous environmental carcinogens known to cause several types of cancers in humans and experimental animals (1) (2) (3) (4) . Recently, dibenzo[a,l]pyrene (DBP) has emerged as the most potent bacterial and mammary carcinogen known thus far (5, 6) . DBP, a peri-condensed hexacyclic PAH, has been found in cigarette smoke condensate, coal-tar, and in food, water and air contam-inated by the combustion of organic materials (7) (8) (9) . DBP has been shown to be highly mutagenic in the metabolically competent MCL-5 cell line derived from human lymphoblastoid cells (10) . Further, the racemic diastereoisomers (syn-and anti-) also showed very high mutagenic activities in different his-strains of Salmonella typhimurium and in Chinese hamster cells (11) .
Although several members of hexacyclic PAHs showed significant carcinogenicity, much less is known about the metabolic activation and biological effects of this large group of PAHs, except for a few studies reported recently (5, 12, 13) . In general, PAHs require bioactivation in order to exert their biological activities and the major pathway involves the formation of diolepoxides by cytochrome P450-dependent mono-oxygenases and epoxide hydrolase (12) (13) (14) (15) (16) . DBP contains both bay-as well as hindered bay-region (fjord-region) because of an additional aromatic ring compared with benzo[a]pyrene (BP), and therefore, it can be metabolized into three different kinds of sterically hindered diolepoxides, the 11,12-diol-13,14-epoxides, the 1,2-diol-3,4-epoxides and the 3,4-diol-1,2-epoxides (17, 18) . However, the 11,12-diol-13,14-epoxide (hereafter referred as DBPDE) was the most reactive of all the epoxides known so far (17) (18) (19) (20) . Moreover, DBP has been shown to be a stronger carcinogen than its trans-11,12-dihydrodiol or 11,12-diol-13,14-epoxide, which suggests that DBP diolepoxides may not be the major ultimate carcinogens of DBP (6, 20, 21) ; an alternate route of activation, such as one-electron oxidations, may also be involved (5, 6, (21) (22) (23) . Recently, Li et al. (22) have shown that activation of DBP by rat liver microsomes produced six depurinating adducts constituting 84% of all detected adducts. In both initiationpromotion and repeated application studies in the mouse skin model, DBP at low doses (0.25 nmol and 8 nmol) induced more tumors than its metabolite, DBP-11,12-dihydrodiol, and 7,12-dimethylbenz[a]anthracene (DMBA), previously considered to be the most potent mammary carcinogen (21) . However, at doses ജ20 nmol, DBP and DBP-11,12-dihydrodiol were toxic enough to interfere with the induction of tumors whereas the tumorigenicity of less toxic DMBA and BP was increased proportionately with the increase in dose (21) . In another study, LaVoie et al. (24) have shown that DBP at a dose of 1 nmol/mouse induced 95% incidence of tumor-bearing mice with an average of 5.0 tumors per mouse, however, DMBA at the similar dose only produced 1.3 tumors per mouse with an 85% incidence. Further, tumorigenicity of anti-DBPDE was found to be much greater in the newborn mice compared with other hindered bay-region diolepoxide of benzo[g]chrysene and the most active unsubstituted bay region diol epoxide of BP (25) . Relative tumorigenicity of both the syn-and antidiolepoxides of DBP showed that they are much less carcinogenic than their precursors; however, at 1.33 and 4 nmol doses, (Ϯ)-r-11,t-12-dihydroxy-c-13,14-epoxy-11,12,13,14-tetrahydrodibenzo[a,l]pyrene (syn-DBPDE) was about two times more tumorigenic than its congener (Ϯ)-r-11,t-12-dihydroxy-t- 13,14-epoxy-11,12,13,14-tetrahydrodibenzo[a,l] pyrene (anti-DBPDE) (20) .
Like other PAHs, DBP has also been shown to produce both stable and unstable adducts (12, 22, 23, 26, 27) . As many as six depurinated adducts, presumably formed by one-electron oxidation mechanism, have been reported by rat liver microsomal bioactivation of DBP (22, 23) . It has been suggested that the resultant apurinic sites may be responsible for the transforming mutations that lead to papillomas in mouse skin (28) . Much less is known about the identification of stable adducts that remain associated with the DNA. Recent studies have demonstrated that the human breast carcinoma cell line MCF-7 bioactivates DBP stereoselectively to (Ϫ)-anti (11R,12S,13S,14R)-and (ϩ)-syn (11S,12R,13S,14R)-11,12-diol-13,14-epoxides, which bind extensively to deoxyadenosine residues of DNA (18); this finding has been supported by our own study (29) . In another study, Shou et al. (13) have reported that human cytochrome P450 1A1 is the major isozyme involved in the metabolic activation of DBP. In the present study, by using various P450 inducer and inhibitor probes (30), we have elucidated the mechanism of metabolic activation of DBP and characterized the base specificity of DBP-derived DNA adducts by 32 P-postlabeling. We have also characterized the microsome-mediated, stereomeric origin of DNA adducts by co-chromatography with the DNA adduct standards derived from (Ϯ)-syn-and (Ϯ)-anti-DBPDEs.
Materials and methods
Chemicals DBP (Ͼ99%), syn-DBPDE; Ͼ98% and anti-DBPDE; Ͼ98% were received from the National Cancer Institute Chemical Carcinogen Repository, Bethesda, MD, and were used without further purification. NADP ϩ , glucose-6-phosphate, glucose-6-phosphate dehydrogenase, β-naphthoflavone (β-NF), α-naphthoflavone (α-NF), cyclohexene oxide (CHox) and calf thymus DNA (CT-DNA) were obtained from Sigma Chemical Co. (St Louis, MO). CT-DNA was further purified by treatments with RNase A and T1, and proteinase K, followed by solvent extractions and precipitation with ethanol (31, 32) . Other chemicals and solvents used for 32 P-postlabeling were described elsewhere (31) (32) (33) (34) .
Microsomal activation of DBP
Rat liver microsomes were prepared from male SpragueϪDawley rats treated with Aroclor 1254 (500 mg/kg) or β-NF (80 mg/kg) in 1 ml corn oil (35) . DBP (10, 50 and 100 µM), dissolved in tetrahydrofuran (final concn. ഛ2%), was incubated with the Aroclor 1254-or β-NF-induced microsomes (2 mg protein/ml), CT-DNA or deoxynucleoside 3Ј-mononucleotides (dGp, dAp, dCp and dTp) (300 µg/ml), and a NADPH-regenerating system in 50 mM TrisϪHCl buffer, pH 7.4. For the inhibitor studies, the reaction mixture was pre-incubated with the inhibitors, α-NF (50 µM) and/or CHox (100 µM) for 10 min at 37°C. After incubation for 1 h in a shaking water bath at 37°C, the reaction was terminated by centrifugation (5000 r.p.m., 5 min) to remove the microsomal proteins (30) . Samples were extracted three times with watersaturated ethyl acetate to remove unreacted metabolites or the parent compound. The aqueous phase was briefly evaporated to remove ethyl acetate and then the DNA was further purified by enzymatic treatments and solvent extractions as described below.
DNA isolation
DNA was isolated by a rapid procedure of treatment with RNAses and proteinase K to remove RNA and protein, respectively, followed by extraction with phenol, phenol:sevag (chloroform:isoamylalcohol, 24:1) and sevag. DNA was recovered by ethanol precipitation (32) . Nucleotides were purified only by extraction with ethyl acetate as described above. The purified DNA and nucleotides were dissolved in sodium chloride (1.5 mM)Ϫsodium citrate (0.15 mM)Ϫ0.1 mM EDTA (SSCϪEDTA). Purified DNA was virtually free of RNA and protein contamination; the DNA concentration was measured spectrophotometrically (1 A 260 ϭ 50 µg DNA).
Reaction of syn-and anti-DBP diolepoxides with CT-DNA and nucleotides Syn-and anti-DBPDEs (100 µM) dissolved in dimethylsulfoxide (final concentration ഛ2%) were incubated with or without CT-DNA (1000 µg/ml), dGp 2000 and dAp (750 µg/ml) in 50 mM TrisϪHCl buffer, pH 7.4. After incubation at 37°C for 2 h, the samples were extracted with water-saturated ethyl acetate as described above. DNA was recovered by ethanol precipitation and the modified DNA and nucleotides were dissolved in SSCϪEDTA solution.
Analysis of DNA adducts by 32 P-postlabeling
The nucleotide and DNA samples were analyzed by 32 P-postlabeling, after enrichment of adducts with nuclease P1 (36) after modifications (32) or nbutanol extraction (32) . Briefly, DNA (15 µg) was digested with micrococcal nuclease and spleen phosphodiesterase (enzyme/substrate, 1:5, w/w, 5 h, 37°C). Adducts were enriched either by nuclease P1 (enzyme/substrate, 1:3, w/w, 45 min, 37°C) or n-butanol extraction and labeled by T4 polynucleotide kinase (0.2 U/µl)-catalyzed phosphorylation in the presence of molar excess of [γ-32 P]ATP (100 µCi; ഛ2 µM;~3000 Ci/mmol) (32) . Untreated and treated nucleotides were analyzed as described above, except that the DNA digestion step was omitted. DBPDE-modified DNAs were digested and enriched with nuclease P1 as above, followed by a 50-fold dilution with water before labeling. An aliquot (~0.2 µg DNA) was labeled with 10 µM ATP [nonradioactive ATP (140 pmols) and [γ-32 P]ATP (30 µCi, 10 pmols)] to avoid ATP deficiency. Anti-DBPDE was also 32 P-labeled directly to determine its substrate specificity towards T4 polynucleotide kinase. Labeled adducts were resolved by multidirectional PEI-cellulose TLC using the solvent systems described in Table I . Adducts were located by intensifying screen-enhanced autoradiography using Cronex-4 X-ray or Kodak XAR-5 films and the radioactivity was measured on Packard Instant Imager. To calculate adduct levels as relative adduct labeling (RAL), total nucleotides were analyzed by labeling a dilute DNA digest (~2.0 ng) in parallel with adducts, followed by separation of normal nucleotides in 1.2 M ammonium formate, pH 3.5 (32) .
Co-chromatography of DBPϪDNA and nucleotide adducts
Labeled digest of DBPϪDNA adducts were analyzed by mixing with labeled DBP-nucleotide adducts. In additional experiments, individual labeled adducts were first eluted off the chromatogram prior to co-chromatography with labeled DNA digest. The experimental strategies were as follows:
Experiment A. Adducts derived from calf thymus DNA and individual nucleotides, dGp and dAp (15 µg) were prepared in 32 P-labeled form by nuclease P1-version (DNA adducts) or butanol-version (nucleotide adducts) of the 32 P-postlabeling assay. An aliquot of these labeled digests was chromatographed in order to determine the adduct radioactivity per unit DNA or nucleotide. Appropriate amounts of the labeled DNA and nucleotide digests were then mixed and resolved by multi-directional PEI-cellulose TLC using solvent systems described in Table I .
Experiment B.
Individual labeled DNA adducts derived from microsomal activation of DBP as well as those derived from syn-and anti-DBPDEs were prepared by nuclease P1-mediated 32 P-postlabeling using 5-20 µg DNA. Labeled adducts were eluted from the PEI-cellulose layer with 6 M pyridinium formate, pH 4.5 (33) . The radioactive eluate was centrifuged, lyophilized, and dissolved in 300 µl H 2 O. The eluate was re-lyophilized to remove residual pyridinium formate. This process was repeated once more and the residue was finally reconstituted in 100-300 µl water. Approximately 200-500 c.p.m. per adduct individually or in different combinations, as described in the Result section, were spotted on 20 ϫ 20 cm PEI-cellulose sheets, and the sheets were developed one-directionally in multiple solvents: 4 M lithium formate/ 7 M urea, pH 3.8; 0.4 M ammonium hydroxide; or isopropanol:4 M ammonium hydroxide (1:1).
Experiment C. In another experiment, labeled digest of microsomal DBPϪDNA adducts (Experiment A) was chromatographed by multidirectional TLC using solvents I and II (Table I ) with or without spiking with individual labeled adducts of syn-and anti-DBPDE as prepared in Experiment B.
Results

Microsomal DBPϪDNA adduction
Preliminary experiments were performed first for standardizing 32 P-postlabeling assay for DBPϪDNA adducts in terms of the choice of adduct enrichment and chromatographic separations.
Recovery of DBPϪDNA adducts by nuclease P1 versus butanol
In order to compare the recovery of DBPϪDNA adducts in the two commonly used enrichment procedures, adducts were enriched with both the nuclease P1 and n-butanol. Nuclease P1-enriched samples produced at least eight adducts (Figure 2A) . However, enrichment with n-butanol showed two additional faster migrating, minor adducts (no. 8 and no. 9) ( Figure 2B ). Quantitation of total DBPϪDNA adducts showed that butanol enriched DNA adducts were~60% lower than the levels determined by using the nuclease P1 procedure. 32 P-Labeling of anti-DBPDE alone as the substrate for T4 polynucleotide kinase produced at least one adduct-like spot (no. c1) ( Figure 2C ), presumably because of non-specific labeling of DBPDE hydrolysis product(s). However, no adduct-like spot was detected when DBPDE was removed by extraction with ethyl acetate, suggesting that DBPϪDNA and nucleotide adduct spots presented here are unrelated to any non-specific labeling of DBP products per se. Resolution of DBPϪDNA adducts The 32 P-postlabeled, nuclease P1-enriched digest of DBPmodified DNA was chromatographed in three different solvent systems as described in Table I to determine maximal adduct resolution. When chromatographed in the commonly used urea solvents (33) (solvent III), the DNA adducts appeared in the 2001 Fig. 2 . Recovery of microsome-mediated DBPϪDNA adducts by nuclease P1 and butanol enrichment-mediated 32 P-postlabeling and non-specific labeling of DBP diolepoxide (DBPDE). Panel (A) nuclease P1 enrichment; panel (B) n-butanol enrichment; panel (C) non-specific labeling of anti-DBPDE-derived hydrolysis products without any enrichment. Aliquots of 4 µg DNA were loaded and adducts were detected by screen-enhanced autoradiography on Dupont Cronex-4 film at room temperature for 45 min (panels A and B). For non-specific labeling of hydrolysis products of DBPDE, anti-DBPDE (100 µM) was labeled directly and 10 µl of labeled digest was loaded and the autoradiography on Cronex-4 film was done for 1 h at room temperature. Table I. form of a diagonal radioactive zone (Figure 3 ). Solvent systems I and II, which involves either one or both of the solvents as urea-free, furnished much better resolution of adducts than did the urea solvents in both directions. Solvent system II [D1 ϭ 1.0 M sodium phosphate, pH 6.0; D3 ϭ 4.0 M lithium formate/ 7.0 M urea, pH 3.5; D4 ϭ isopropanol:4.0 M NH 4 OH (1.1:1)] was used in all subsequent studies, unless otherwise specified.
Effects of P450-specific inducers and inhibitors on microsomal DBPϪDNA adduction
A dose-dependent increase in the DNA adduct levels was found with the increasing concentration of DBP in the range inducers, β-naphthoflavone (β-NF) and Aroclor 1254 on the microsomal DNA adduction of DBP. DBP (50 µM) was incubated with 2 mg/ml microsomal protein from uninduced and induced rat liver in the presence of NADPH-regenerating system for 1 h at 37°C and the reaction was terminated by adding 0.1 mM EDTA followed by centrifugation to remove protein. DNA was isolated and analyzed by 32 P-postlabeling. An aliquot of 2 µg DNA was loaded and autoradiography was done on Dupont Cronex-4 film for 1 h at room temperature except for the panel (B) (uninduced) which was exposed for 5 h at Ϫ80°C.
of 10-100 µM in the presence of either uninduced or β-NFinduced microsomes (Table II) . All subsequent studies were therefore conducted with an intermediate dose of DBP, i.e. 50 µM. Metabolic activation of DBP (50 µM) with β-NF-or Aroclor 1254-induced rat liver microsomes each resulted in one major (no. 6, presumably comprised of two isomeric forms) and at least seven other prominent (nos 2, 3a and b, 4, 5 and 7) DNA adducts as analyzed by nuclease P1-enhanced 32 P-postlabeling assay ( Figure 4C and D, respectively) . Adduct 3 resolved into two distinct identities (3a and 3b) when the D4 development was performed for a longer period of time (5 cm onto a 2002 Fig. 5 . Levels of DBPϪDNA adducts from uninduced and induced rat liver microsomes as shown in Figure 4 . Individual DNA adducts were quantitated on Packard Instant Imager and relative adduct level (RAL) was calculated as described (32) . Adducts 2 and 3 were counted together because of insufficient resolution. Inset figure shows total DNA adducts/10 7 nucleotides.
Whatman 1 paper wick instead of 2-2.5 cm wick. Adduct 6 also separated into two components when the D4 development was performed on a longer (20 cm instead of 10 cm) sheet (data not shown). Essentially similar adduct pattern was obtained when microsomes from uninduced rats were used, except that the adduct spots were much weaker ( Figure 4B ) and adduct 6 was not the most prominent adduct; no adducts were detected in vehicle-treated DNA ( Figure 4A ). Measurement of the adduct radioactivity derived from β-NF-induced microsomes showed ജ20-fold increase in DNA adduction (450 adducts/10 7 nucleotides) as compared with uninduced microsomes (21 adducts/10 7 nucleotides) ( Figure 5 ). This increase was more pronounced (ജ60 fold) with Aroclor 1254-induced microsomal activation (1275 adducts/10 7 nucleotides). Adduct 6 was the major adduct found with both Aroclor-1254-and β-NF-induced microsomes comprising ജ30% of the total adduct radioactivity, with uninduced microsomes, it was adduct 4 that predominated (~37% of the total adducts). Addition of α-naphthoflavone (α-NF, 50 µM), a known inhibitor of CYP1A1 (30) , to the activation system containing β-NF-induced microsomes, almost completely (Ͼ98%) inhibited DNA adduction ( Figure 6 ). A similar inhibition (Ͼ98%) was also found when Aroclor 1254-induced microsomes were substituted for β-NFinduced microsomes in the reaction mixture (data not shown) supporting the fact that CYP1A1 is the major isozyme involved in DBP bioactivation. However, cyclohexene oxide (CHox, Fig. 6 . Levels of microsome-mediated DBPϪDNA adducts in the presence of α-NF (50 µM) and CHox (100 µM) inhibitors. DBP (50 µM) was incubated with 2 mg/ml protein from β-NF-induced rat liver microsomes in the presence of specific inhibitors and NADPH-regenerating system for 1 h at 37°C (see Figure 4 legends for further details). Individual DNA adducts were quantitated on a Packard Instant Imager and relative adduct level (RAL) was calculated as described (32) . Inset figure shows total DNA adducts/10 7 nucleotides. Fig. 7 . Co-chromatography of individual 2Ј-deoxynucleosides 3Ј-mononucleotides (dGp and dAp) and DNA adducts derived from microsomal adduction of DBP. Appropriately labeled DBPϪDNA adducts were mixed with adducts from dGp and dAp after CPM adjustment and were loaded onto PEI-cellulose sheets and developed on multidirectional TLC in the solvent systems described in Table I . The maps are shown for the solvent system II. Autoradiography was done on Kodak XAR-5 film for 2 h at Ϫ80°C. 100 µM), a known inhibitor of epoxide hydrolase (37), was found to be only slightly (~20%) inhibitory in the present activation system (Figure 6 ). Further, a combination of α-NF and CHox exhibited the same effect as observed with α-NF alone ( Figure 6 ).
Reactivity of microsomes-mediated DBP metabolites with mononucleotides
Incubation of 2Ј-deoxynucleoside 3Ј-mononucleotides (dAp, dGp, dCp and dTp) with DBP and β-NF-induced microsomes, followed by adduct analysis, showed that only purines formed adducts (Figure 7) . Reaction of dGp resulted in at least four adducts (no. 1Ϫno. 4), with adduct 1 predominating ( Figure 7B ), while dAp produced three adducts (no. 5Ϫno. 7), with adduct 7 forming almost exclusively ( Figure 7A) ; no adduct was detected with dCp and dTp (not shown). The nucleotide adducts could not be quantified because of partial dephosphorylation of the 3Ј-nucleotides during the microsomal reaction, as shown by only 10-30% recovery in the 32 Plabeling analysis of the normal nucleotides (data not shown). DNA adducts derived from syn-and anti-DBPDEs Anti-DBPDE (100 µM) incubated with CT-DNA produced six major (spots a1Ϫa4, a6, a7) and at least two minor (spots a5, a8) adducts (Figure 8 ). Reaction with dGp resulted in four adducts (Figure 8 , spots a1Ϫa4), while three adducts were detected with dAp ( Figure 8, spots a6Ϫa8) . Measurement of the adduct radioactivity revealed that dA (80 000 adducts/10 7 nucleotides) was somewhat more reactive than dG (65 000 adducts/10 7 nucleotides) but about three times more adducted than DNA (31 000 adducts/10 7 nucleotides). Chromatographic comparison suggested that the major adducts a1Ϫa4 in the DNA were dG-derived, while the other two major (a6, a7) and one minor (a8) adducts were dA-derived. Interestingly, adduct a8, which was formed only as a minor adduct (Ͻ2% of the total binding) at the DNA level, was formed predominantly (Ͼ35%) at the nucleotide level, suggesting possible interference of the DNA double helix or chirality of DNA for anti-DBPDE to bind to the specific site of deoxyadenosine in the DNA. Adduct 5 remained unidentified as it was present only in traces (Ͻ1%).
The syn-DBPDE also produced multiple adducts when incubated with DNA and nucleotides: seven adducts with DNA (Figure 8 ), four adducts with dGp (Figure 8) , and two adducts with dAp ( Figure 8) ; no attempts were made to characterize the minor adduct s7 as it was present in traces (1-2%). However, the respective adduct patterns resulting from the two stereoisomers were quite distinct and anti-DBPDE was 3-10 times more reactive than the syn-isomer. Chromatographic comparisons of the syn-DBPDE-derived DNA and nucleotide adducts suggested that the major adducts s1Ϫs4 were dGderived, while the other major adducts (s5 and s6) were dA-derived. (Table I) and autoradiographic detection was for 6 h at Ϫ80°C.
Identification of microsomal DBPϪDNA adducts DNA adducts resulting from microsomal bioactivation of DBP were identified, in terms of the base selectivity and the stereoisomeric nature of DBPDE, by co-chromatography with DNA and nucleotide adducts produced by reaction with antiand syn-DBPDEs.
Co-chromatography of the DNA adducts with dGp-and dAp-derived adducts, all resulting from microsomal DBP activation, showed that the DNA adducts 1-4 co-migrated with dG adducts, while adducts 5-7 co-migrated with dA adducts (Figure 7) , suggesting that the DNA adducts 1-4 were dG-derived while adducts 5-7 were dA-derived. These results were confirmed in multiple TLC solvents (Table I) . Individual DNA adducts from microsomal DBP activation ( Figure 4C ) and from anti-and syn-DBPDEs ( Figure 8) were eluted from the thin layer and spotted individually or after mixing with appropriate candidate adduct(s) (~200-500 c.p.m. each) on PEI-cellulose thin layers (20 ϫ 20 cm) and the chromatograms were developed one-directionally in different solvents. The results obtained in this approach were confirmed by spiking the labeled digest of microsome-activated DBPϪDNA with the individual syn-or anti-DBPDEϪDNA adducts and chromatographing by multidirectional PEI-cellulose TLC using solvents described in Table I (Figure 9 ).
Results compiled in Table III , in conjunction with the data described above, reveal that microsomal DBPϪDNA adducts can be labeled as follows: (i) adduct 1, dG-derived, resulted from anti-DBPDE as it co-migrated with adduct a1 ( Figure 9D) ; (ii) adduct 2, dG-derived, is formed from the syn-isomer because it co-migrated with the syn-isomer adducts s1 ( Figure 9A) ; adduct 3a, dG-derived, resulted from syn-DBPDE because of its co-migration with adduct s2 (Figure 9A ), while adduct 3b was most probably derived from anti-DBPDEϪdG since it co-migrated with adduct a4 ( Figure 9F ); (iii) adduct 4, derived from dG, resulted from syn-DBPDE because of its co-migration with s4 ( Figure 9D ); (iv) adduct 5, derived from dA, co-migrated with the syn-isomer adduct s5 ( Figure 9F ; also revealed from one-directional map, not shown); (v) adduct 6 comprised of two components, both derived from dA may have resulted from both syn-and anti-isomers because of comigration with adducts s6 and a6 ( Figures 9A and B) ; and (vi) adduct 7, dA-derived, resulted from anti-DBPDE because of its co-migration with adduct a8 (Figure 9F ). Based on these results, the microsomal DBPϪDNA adducts can be assigned as indicated in Figure 10 .
Discussion
The present study demonstrates that (i) DBP can be bioactivated by both uninduced and induced (Aroclor 1254 or β-NF) rat liver microsomes; (ii) metabolic activation of DBP requires mainly cytochrome P450 1A (CYP1A) family and epoxide hydrolase (EH) leading to the formation of one predominant and seven prominent DNA adducts; (iii) both dG and dA contributed nearly equally in the binding of DBP to DNA and the predominant (Ͼ30%) adduct was adenine-derived; no adducts were detectable with dC or dT; and (iv) both syn-and anti-DBPDEs contributed in microsomal DNA adduction.
Bioactivation of DBP appears very comparable to that of BP (30) . Microsome-mediated DBPϪDNA adduction was enhanced many fold with β-NF-(™20 fold) and Aroclor 1254 (™60 fold)-induced microsomes compared with the uninduced microsomes, which suggests the involvement of primarily CYP1A family and its dependent mono-oxygenases in the bioactivation of DBP; however, possible involvement of other P450 isozymes cannot be excluded. Further, evidence of CYP1A1 involvement in DBP activation was confirmed by the addition of α-NF, a selective inhibitor of CYP1A1 subfamily, which almost completely (Ͼ98%) abolished the DBPϪDNA binding (30, 38) . A similar inhibition of all the DBP-derived DNA adducts was also observed with Aroclor 1254-induced microsomes, a broad spectrum P450 inducer, further suggesting the involvement of CYP1A1 family in DBP bioactivation. Recent reports (13, 39) on the involvement of CYP1A1 in the conversion of DBP to trans-11,12-dihydrodiol also support our results; however, the involvement of other isozymes of cytochrome P450 (1A2, 2C9, 2B6, 3A4 etc.) cannot be excluded in the activation of this compound (13, 39) . Activation of trans-11,12-dihydrodiol to the ultimate metabolite, 11,12-diol-13,14-epoxide, requires EH along with P450 (most probably CYP1A1) (13, 17, 18, 26, 39) . Modulation of adduct formation in the presence of EH inhibitors suggest the type of epoxide formed: adducts derived from a single-step epoxidation may increase in the presence of EH inhibitor while adducts produced by two-step conversion of the parent compound to a diolepoxide may actually decrease because of lack of formation of a prerequisite intermediate, a trans-11,12-dihydrodiol (13, 39, 40) . In several studies, investigators have reported that metabolic activation of DBP requires two consecutive oxidation steps at 11,12-and 13,14-positions (13, 17, 18) . Therefore, the 11,12-dihydrodiol could be an essential intermediate metabolite of DBP, which was further supported by complete abolition of DBPϪDNA adduct formation by inhibiting the CYP1A1 with α-NF. Although the inhibition of DBPϪDNA adduction was not significant in the presence of 
DNA adducts were eluted individually from anti-and syn-DBPDEs with 6.0 M pyridinium formate, pH 4.5 and after c.p.m. adjustment, they were used for spiking the labeled DNA digest of microsome activated DBP and the maps were chromatographed in different solvents systems as described in Materials and methods. a Solvent systems I and II: as described in Table I . CHox [an inhibitor of microsomal EH (99%) with Ͻ1% cytochrome P450 activity; 30, 37] in the present activation system, it is clear from our co-chromatographic results with DBPDEs and the work of others (13, 17, 18, 39 ) that a two-step activation pathway is involved in the bioactivation of DBP. Structurally, DBP produce 1 bay-and 2 fjord-region diol epoxides; other additional higher hydroxylated derivatives of these diolepoxides could also be possible (17) . Further, the structure of DBP may make the oxidation of the 1, 2, 3, 4-positions less favorable and therefore the activation is mostly favored towards the 11,12-diol-13,14-epoxide, which is presumably a more potent ultimate carcinogenic metabolite than the bay-region diolepoxides (17, 24, 41) . Microsome-mediated DBP-derived DNA adducts observed in the present study also support the above hypothesis, by being chromatographically identical to syn-or anti-DBP -11,12-diol-13,14-epoxides. In the present study, the respective DNA adduct standards were prepared by reacting the racemic mixture of (Ϯ)-antiand syn-DBPDEs with CT-DNA. Anti-DBPDE by interaction with DNA produced four major guanine-derived adducts, and two major and one minor adducts were derived from adenine. Adduct a8 (Figure 8 ) was formed as a minor adduct (Ͻ2%) upon reaction with (native) DNA, while at nucleotide level, it formed as a major adduct (Ͼ35%). This suggests that certain adenine-rich DNA sequences are somehow protected in the double helical DNA limiting its potential formation in the cultured cells and in vivo situations (30, 42, 43) ; further, chirality of DNA could also be attributed in explaining the phenomenon.
Syn-DBPDE also produced six major DNA adducts, four 2005 derived from guanine and two adducts from adenine ( Figure  8 ). Co-chromatography of microsomal DBPϪDNA adducts with the adducts derived from syn-or anti-DBPDEs showed that nearly one-half of the adducts were derived from syn-and the other half from anti-DBPDE derived. Complete structures of the stable adducts as investigated in this study remain yet to be identified. The major unstable (depurinated) adducts are reported to be formed by interaction of DBP at N-3 and N-7 of adenine (22, 23) . Considering that the N-2 position of dG is the predominant site of formation of many PAHϪDNA adducts, it is plausible that the major DBP adducts are derived by interaction of anti-and syn-DBPDE at the exocyclic N-2 position of guanine and N-6 position of adenine. The present findings indicate that both adenine and guanine residues in the DNA are modified by the DBP and that over 50% of the total microsomal DNA adducts are caused by interaction with adenine. The major adduct 6 from microsomal activation of DBP, which appeared to be resolved in two distinct adducts during longer chromatographic run on 13 ϫ 20 sheets, may be derived partly or completely from either synor anti-DBPDEs since it co-migrated with both s6 and a6. However, it is clear from the present study that this adduct was formed with only dA, which is in agreement with the data of Ralston et al. (18) who showed that the predominant adduct of DBP in human MCF-7 cell line is adenine-derived. Further, at least four minor adducts derived from both anti-and syn-DBPDE were also found to be dG-derived, which is also consistent with the data of Ralston et al. (18) . Our results along with the published report (18) suggest that adenine in the DNA is the major site of adduction with DBP after activation with rat liver microsomes as well as with the human MCF-7 cell line. In another study reported elsewhere, we have shown that 70% of the total DNA adducts in different tissues of rats treated with intramammilary, i.p. and gavage routes, were adenine-derived (42, 43) . The extensive binding of DBP metabolites to adenine residues in DNA, as reported previously for DMBA (44) , benzo[c]phenanthrene (45, 46) and benzo[g]chrysene (47), may actually be responsible for its exceptionally high carcinogenicity in rodents (6, 20, 21) . However, other factors such as relative repair rates of the DBPϪDNA adducts may also play an important role in the high carcinogenicity of DBP.
In conclusion, the present study may provide an insight into the formation and characterization of DBP-derived stable DNA adducts by 32 P-postlabeling in the target and non-target tissues in vivo and subsequently their roles in the assessment of mutagenic and carcinogenic potential of individual DNA adducts.
